| abstract |
Methods for treating a cancer having a mutant isocitrate dehydrogenase (IDH), including, but not limited to, a malignant low-grade glioma, a secondary glioblastoma, a transforming myeloproliferative disorder (tMPD), and an acute myelogenous leukemia (AML), with a glutaminase inhibitor, including, bis- 2 -( 5 -phenylacetamido- 1,2,4 -thiadiazol- 2 -yl)ethyl sulfide (BPTES), are disclosed. |